Ginsenoside Rg5

CAS: 186763-78-0

Ref. TM-T6S1487

Produktinformation

• Name: Ginsenoside Rg5
• Synonyme: Ginsenoside Rg-5, (3β,12β,20E)-12-Hydroxydammara-20(22),24-dien-3-yl 2-O-β-<span class="text-smallcaps">D</smallcap>-glucopyranosyl-β-<smallcap>D</span>-glucopyranoside, (8xi,9xi,12alpha,13xi,14beta,17beta)-17-[(1E)-1,5-dimethylhexa-1,4-dien-1-yl]-12-hydroxy-4,4,7,10,14-pentamethylgonan-3-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside, G-Rg5, Ginsenoside Rg5E, Ginsenoside Rg₅, beta-D-Glucopyranoside, (3beta,12beta,20E)-12-hydroxydammara-20(22),24-dien-3-yl 2-O-beta-D-glucopyranosyl-, β-<span class="text-smallcaps">D</smallcap>-Glucopyranoside, (3β,12β,20E)-12-hydroxydammara-20(22),24-dien-3-yl 2-O-β-<smallcap>D</span>-glucopyranosyl-
• CAS: 186763-78-0

Beschreibung

1. Ginsenoside Rg5 could be a beneficial agent for the treatment of Alzheimer's disease. 2. Ginsenoside Rg5 suppresses LPS-induced nitric oxide (NO) production and proinflammatory TNF-α secretion. 3. Ginsenoside Rg5 can ameliorate lung inflammation possibly by inhibiting the binding of LPS to toll-like receptor (TLR)-4 on macrophages. 4. Ginsenoside Rg5 plays a novel role as an IGF-1R agonist, promoting therapeutic angiogenesis and improving hypertension without adverse effects in the vasculature. 5. Ginsenoside Rg5 blocks cell cycle of SK-HEP-1 cells at the Gl/S transition phase by down-regulating cyclin E-dependent kinase activity and that the down-regulation of cyclin E-dependent kinase activity is caused mainly by induced CDK2 inhibitor, p21Cip/WAF1 and decreased levels of cyclin E.

• Marke: Targetmol

Chemische Eigenschaften

• Molekulargewicht: 767
• Formel: C₄₂H₇₀O₁₂
• Reinheit: 98%
• Farbe/Form: Solid